Core Viewpoint - Bavarian Nordic A/S has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million, following the approval of its chikungunya vaccine, VIMKUNYA™ [1] Group 1: Financial Impact - The National Institutes of Health (NIH) will receive 20% of the gross proceeds from the sale of the PRV, which will be recognized as other operating income [2] - The sale proceeds will not impact the guided revenue expectations for 2025, but EBITDA will be positively impacted, with updates on the EBITDA margin of 26-30% for 2025 to be provided upon closing of the transaction [2] Group 2: Transaction Details - The transaction is subject to customary closing conditions, including an anti-trust review expected in the third quarter of 2025 [3] - Jefferies LLC acted as the exclusive financial advisor to Bavarian Nordic for this transaction [3] Group 3: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, with a strong portfolio in mpox and smallpox vaccines, as well as travel vaccines [4]